Sign in

You're signed outSign in or to get full access.

Finepoint Capital LP

CIK:0001608126
Hedge Fund
$4B AUM
10 holdings
Boston, MA, United States
Founded:2013
20 employees
Latest filing:Jun 30, 2025

FINEPOINT CAPITAL LP is a Boston-based hedge fund and private investment firm founded in 2013 by Herb Wagner. The firm specializes in providing growth capital and strategic support to companies, focusing especially on technology, healthcare, and consumer sectors. It operates as a portfolio management firm and registered investment adviser, and employs around 18–20 investment professionals and staff. Finepoint Capital primarily serves institutional clients and high-net-worth individuals seeking long-term, risk-adjusted returns, leveraging the expertise of an experienced investment team and deep industry networks.

Investment Strategy

Finepoint Capital employs a multi-strategy, global investment approach with a focus on achieving attractive absolute returns on a long-term, risk-adjusted basis. The firm seeks investments in both public and private companies, emphasizing innovation in technology, healthcare, and consumer sectors. Finepoint looks for opportunities in companies disrupting traditional industries or employing innovative business models, favoring those with strong management teams and significant growth prospects. The firm provides not only capital, but strategic and operational guidance, leveraging industry expertise to assist portfolio companies in scaling and achieving long-term objectives. Portfolio construction typically features a mix of concentrated positions and selective risk management through hedges and opportunistic trades.

Latest 13F Filing Activity

Finepoint Capital LP filed their most recent 13F report on Jun 30, 2025 disclosing 4 equity positions and 2 options positions with a total 13F market value of $1B. The fund increased holdings in Qxo Inc., Liberty Media Corp. Del, Solid Biosciences Inc. among other positions. Finepoint Capital LP reduced exposure to Liberty Broadband Corp., Springworks Therapeutics Inc., Ascendis Pharma A/s among others.

Top Buys
Q
QXOQXO INC
+$124.3M
L
LLYVKLIBERTY MEDIA CORP DEL
+$14.1M
S
SLDBSOLID BIOSCIENCES INC
+$1.1M
C
CLDICALIDI BIOTHERAPEUTICS INC
-$4.2K
Top Sells
L
LBRDKLiberty Broadband Corp
-$45.0M
S
SWTXSPRINGWORKS THERAPEUTICS INC
-$32.2M
A
ASNDASCENDIS PHARMA A/S
-$28.0M
R
RVMDREVOLUTION MEDICINES INC
-$24.4M
M
MLTXMoonLake Immunotherapeutics
-$17.0M

Top Holdings

Q
QXOQXO INC
+33.6%$455.6M
L
LLYVKLIBERTY MEDIA CORP DEL
+3.2%$43.6M
S
SLDBSOLID BIOSCIENCES INC
+0.3%$4.7M
C
CLDICALIDI BIOTHERAPEUTICS INC
+0.0%$2.9K

Equity Positions (4)

TickerSecurityWeightMarket ValueSharesAvg CostPriceChange (QoQ)
QXO INC33.61%$455.6M21,152,868$15.77$21.54+$124.3M
LIBERTY MEDIA CORP DEL3.22%$43.6M537,051$70.60$81.16+$14.1M
SOLID BIOSCIENCES INC0.35%$4.7M961,251$5.13$4.87+$1.1M
CALIDI BIOTHERAPEUTICS INC0.00%$2.9K12,499$1.14$2.76-$4.2K

Options Positions (2)

TickerSecurityActionTypeNotional ValueContractsUnderlying PricePremium PaidChange (Contracts)Change (Value)
SPDR S&P 500 ETF TRBought
Put
$725.0M11,735$617.85$591.58+4,185+$302.9M
ISHARES TRSold
Put
$126.2M5,850$215.79$220.91-9,000-$170.0M

Industry Allocation

WHOLESALE-LUMBER & OTHER CONSTRUCTION MATERIALS
+24.4%
TRANSPORTATION SERVICES
+6.4%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+0.3%

Investment Team (12)

NameRoleLocationLinkedIn
Baily Dent
Baily Dent
Managing DirectorBoston, MA , United States
Chang Lee
Chang Lee
Investment AnalystBoston, MA , United States
J
Justin Dancu
AnalystBoston, MA , United States
Kevin Koslosky
Kevin Koslosky
PartnerBoston, MA , United States
R
Rebecca Nordhaus
PartnerBoston, MA , United States
Serena Jeon
Serena Jeon
Investment AnalystNew York, NY , United States
T
Tim Caflisch
PartnerBoston, MA , United States
A
Akinori Oshiro
Investment AnalystBoston, MA , United States
A
Alec Williams
AnalystUnited States
F
Fukuhara
Incoming Junior AnalystGrinnell, IA , United States
Showing 1-10 of 12 team members